223 related articles for article (PubMed ID: 9845091)
1. Bioreductive therapies: an overview of drugs and their mechanisms of action.
Rauth AM; Melo T; Misra V
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):755-62. PubMed ID: 9845091
[TBL] [Abstract][Full Text] [Related]
2. Bioreductive drugs as post-irradiation sensitizers: comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9.
Adams GE; Stratford IJ; Edwards HS; Bremner JC; Cole S
Int J Radiat Oncol Biol Phys; 1992; 22(4):717-20. PubMed ID: 1544844
[TBL] [Abstract][Full Text] [Related]
3. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.
Guise CP; Mowday AM; Ashoorzadeh A; Yuan R; Lin WH; Wu DH; Smaill JB; Patterson AV; Ding K
Chin J Cancer; 2014 Feb; 33(2):80-6. PubMed ID: 23845143
[TBL] [Abstract][Full Text] [Related]
4. Bioreductive therapy.
Chaplin DJ
Int J Radiat Oncol Biol Phys; 1992; 22(4):685-7. PubMed ID: 1544837
[No Abstract] [Full Text] [Related]
5. The experimental development of bioreductive drugs and their role in cancer therapy.
Workman P; Stratford IJ
Cancer Metastasis Rev; 1993 Jun; 12(2):73-82. PubMed ID: 8375022
[TBL] [Abstract][Full Text] [Related]
6. Bioreductive drugs in cancer therapy.
Stratford IJ
BJR Suppl; 1992; 24():128-36. PubMed ID: 1341908
[No Abstract] [Full Text] [Related]
7. The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins.
Walton MI; Sugget N; Workman P
Int J Radiat Oncol Biol Phys; 1992; 22(4):643-7. PubMed ID: 1544831
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxicity of dual function nitrofurans in rodent and human tumor cells.
Siemann DW
Int J Radiat Oncol Biol Phys; 1992; 22(4):697-700. PubMed ID: 1544840
[TBL] [Abstract][Full Text] [Related]
9. Nitroimidazoles as anti-tumor agents.
Liu K; Zhu HL
Anticancer Agents Med Chem; 2011 Sep; 11(7):687-91. PubMed ID: 21521156
[TBL] [Abstract][Full Text] [Related]
10. Assessment of a range of novel nitro-aromatic radiosensitizers and bioreductive drugs.
Fielden EM; Adams GE; Cole S; Naylor MA; O'Neill P; Stephens MA; Stratford IJ
Int J Radiat Oncol Biol Phys; 1992; 22(4):707-11. PubMed ID: 1544842
[TBL] [Abstract][Full Text] [Related]
11. Bioreductive mechanisms.
Workman P
Int J Radiat Oncol Biol Phys; 1992; 22(4):631-7. PubMed ID: 1544830
[TBL] [Abstract][Full Text] [Related]
12. The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation.
Keohane A; Godden J; Stratford IJ; Adams GE
Br J Cancer; 1990 May; 61(5):722-6. PubMed ID: 2110815
[TBL] [Abstract][Full Text] [Related]
13. Reaction of the hypoxia-selective antitumor agent tirapazamine with a C1'-radical in single-stranded and double-stranded DNA: the drug and its metabolites can serve as surrogates for molecular oxygen in radical-mediated DNA damage reactions.
Hwang JT; Greenberg MM; Fuchs T; Gates KS
Biochemistry; 1999 Oct; 38(43):14248-55. PubMed ID: 10571998
[TBL] [Abstract][Full Text] [Related]
14. Use of the comet assay to detect hypoxic cells in murine tumours and normal tissues exposed to bioreductive drugs.
Olive PL
Acta Oncol; 1995; 34(3):301-5. PubMed ID: 7779413
[TBL] [Abstract][Full Text] [Related]
15. Bioreductive agents: a clinical update.
Boyer MJ
Oncol Res; 1997; 9(6-7):391-5. PubMed ID: 9406245
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA): implications for bioreductive drug development.
Phillips RM
Biochem Pharmacol; 1999 Jul; 58(2):303-10. PubMed ID: 10423172
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia: targeting the tumour.
Boyle RG; Travers S
Anticancer Agents Med Chem; 2006 Jul; 6(4):281-6. PubMed ID: 16842231
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of oncogenicity for bioreductive drugs.
Hei TK; Piao CQ; He ZY; Hall EJ
Int J Radiat Oncol Biol Phys; 1992; 22(4):747-50. PubMed ID: 1544847
[TBL] [Abstract][Full Text] [Related]
19. Hypobaric hypoxia: a method for testing bioreductive drugs in vivo.
McAleer JJ; McKeown SR; MacManus MP; Lappin TR; Bridges JM
Int J Radiat Oncol Biol Phys; 1992; 23(3):551-5. PubMed ID: 1612955
[TBL] [Abstract][Full Text] [Related]
20. Targeting hypoxia with a new generation of indolequinones.
Jaffar M; Naylor MA; Robertson N; Stratford IJ
Anticancer Drug Des; 1998 Sep; 13(6):593-609. PubMed ID: 9755720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]